AMGNAMGNHealthcare · Drug Manufacturers - General

AMGN Stock Forecast: Amgen, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$436
−0.17% on the day

The 34 Wall Street analysts covering Amgen, Inc. hold a median 12-month price target of $440 — +1.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 95 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$237.4B
Ticker Nerd rank
95/ 100
Median analyst target
$440
Analysts covering
34
Revenue$10.1B+9.5% y/y
Operating income$3.5B
Net income$2.4B
Free cash flow$3.5B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.9%
1M
−0.2%
YTD
+36.6%
1Y
+34.0%
From 52W high
−8.4%
From 52W low
+42.5%
$306
$476
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Amgen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
95/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
98
Volatility
96
Momentum
94
Value
93
Revisions
83
Issuance
73
Growth
70
Accruals
47

Quality (98): The business earns solid, repeatable profits on what it owns.

Accruals (47): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

AMGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AMGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$200$300$400$500$600Jan 26Apr 26Jul 26Oct 26AMGNHigh $542Median $440Low $230

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says34 analysts
11
Buy
18
Hold
5
Sell
$230
Low
$440
Median
$542
High

The green dot is the last close — the median target sits +1.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 20 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
16 Nov 2026BarclaysMaintainsEqual-Weight$400 → $430
12 Nov 2026Argus ResearchMaintainsBuy$460 → $515
6 Nov 2026Freedom BrokerDowngradeHold$450 → $470
5 Nov 2026GuggenheimMaintainsNeutral$378 → $435
5 Nov 2026Leerink PartnersMaintainsMarket Perform$395 → $464
4 Nov 2026BernsteinMaintainsMarket Perform$345 → $400
4 Nov 2026Canaccord GenuityMaintainsHold$384 → $440
4 Nov 2026Cantor FitzgeraldMaintainsNeutral$440 → $465
4 Nov 2026CitigroupMaintainsNeutral$405 → $465
4 Nov 2026Goldman SachsMaintainsBuy$481 → $536
4 Nov 2026JP MorganMaintainsNeutral$350 → $425
4 Nov 2026Morgan StanleyMaintainsEqual-Weight$359 → $410
4 Nov 2026RBC CapitalMaintainsOutperform$430 → $470
4 Nov 2026ScotiabankMaintainsSector Outperform$500 → $530
4 Nov 2026TD CowenMaintainsBuy$452 → $531
4 Nov 2026Truist SecuritiesMaintainsHold$380 → $398
4 Nov 2026UBSMaintainsBuy$470 → $530
4 Nov 2026Wells FargoMaintainsEqual-Weight$430 → $460
23 Oct 2026OppenheimerMaintainsOutperform$450 → $480
21 Oct 2026BarclaysMaintainsEqual-Weight$380 → $400

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for AMGN.

Market Radar

This page is one stock. Monday covers all of them.

AMGN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

AMGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Amgen, Inc. returned +34.0% against +6.9% for the S&P 500, dividends included.

AMGN vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150Jan 26Apr 26Jul 26Oct 26AMGNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AMGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+2.3%
Analysts raising
25
Analysts cutting
2
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
25.7×

Cheaper than 34% of US stocks

Price / sales
6.2×

Cheaper than 18% of US stocks

Price / book
16.7×

Cheaper than 4% of US stocks

EV / EBITDA
15.8×

Cheaper than 31% of US stocks

Growth & margins
Revenue growth (YoY)
8.5%

Higher than 50% of US stocks

Earnings growth (YoY)
20.1%

Higher than 60% of US stocks

Gross margin
72.0%

Higher than 84% of US stocks

Operating margin
34.1%

Higher than 90% of US stocks

Net margin
24.1%

Higher than 84% of US stocks

Returns & dividend
Return on equity
78.4%

Higher than 95% of US stocks

Return on assets
8.9%

Higher than 90% of US stocks

Dividend yield
2.3%

Higher than 48% of US dividend payers

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Amgen, Inc. has a market value of $237.4B and an enterprise value of $278.2B.

  • Revenue in the twelve months to 30 June 2026: $38.1B. The latest quarter grew 9.5% year on year.

  • Net income over the same four quarters: $8.7B, a 23.0% net margin.

  • Diluted earnings per share, trailing twelve months: $16.09.

  • Free cash flow in the twelve months to 30 June 2026: $10.2B.

  • Amgen, Inc. spent $5.3B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 540.6M.

  • Trailing P/E: 25.7×; forward P/E: 17.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 2.29%, paying out 58% of earnings.

  • Amgen, Inc. employs 31,500 people — $1.2M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

AMGN and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
AMGNAmgen, Inc.$237.4B95
GILDGilead Sciences, Inc.$206.6B89
MRKMerck & Co., Inc.$331.9B86
PFEPfizer Inc.$155.8B91
BMYBristol Myers Squibb Co.$119.7B94
ABBVAbbVie, Inc.$505.7B90
JNJJohnson & Johnson$651.8B86

Take a look at AMGN’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Amgen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about AMGN

What is the AMGN stock price forecast for 2026-2027?

The 34 Wall Street analysts covering Amgen, Inc. have a median 12-month price target of $440, with estimates ranging from $230 to $542. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AMGN stock a buy right now?

Of the 34 analysts covering Amgen, Inc., 11 rate it a Buy, 18 a Hold and 5 a Sell. Ticker Nerd's systematic factor model ranks Amgen, Inc. 95 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AMGN?

As at 21 Nov 2026, Amgen, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).

Will AMGN stock go up?

No one can know that. What the data says: the median 12-month target from 34 analysts implies +1.0% from the last close, and Ticker Nerd's factor model ranks Amgen, Inc. 95 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AMGN stock forecast for 2030?

No analyst covering Amgen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $230 to $542 over the next 12 months.

How has AMGN stock performed over the past year?

Amgen, Inc. returned +34.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Amgen, Inc. do?

Amgen Inc. Common Stock represents ownership in Amgen Inc., a biotechnology company focused on discovering, developing, manufacturing, and marketing human therapeutics for serious diseases. The company’s portfolio spans therapies used in oncology, inflammation, cardiovascular conditions, osteoporosis, and rare diseases, making it a significant participant in global biopharmaceutical markets.

Company

About Amgen, Inc.

Amgen Inc. Common Stock represents ownership in Amgen Inc., a biotechnology company focused on discovering, developing, manufacturing, and marketing human therapeutics for serious diseases. The company’s portfolio spans therapies used in oncology, inflammation, cardiovascular conditions, osteoporosis, and rare diseases, making it a significant participant in global biopharmaceutical markets. Amgen also supports its business through biologic manufacturing capabilities and a commercial organization that brings prescription medicines to patients and healthcare providers in multiple regions. As a large-cap healthcare equity, Amgen Inc. Common Stock is widely followed by market participants for its role in the biotechnology sector and its exposure to branded medicines, biologics, and specialty treatment areas.

CEO Mr. Robert A. Bradway · 31,500 employees · United States · https://www.amgen.com